EV / Revenue
Use Average
|
ALTH
Allos Therapeutics, Inc.
|
SNY
Sanofi SA (ADR)
Change
|
DNA
Genentech, Inc.
Change
|
GILD
Gilead Sciences, Inc.
Change
|
AMGN
Amgen, Inc.
Change
|
|
5.39
|
1.29
|
2.25
|
7.2
|
9.42
|
4.58
|
All amounts in millions
from last financial year
|
|
|
|
|
|
|
Implied Share Price
|
$4.74
|
$140.21
|
$71.79
|
$30.08
|
$120.68
|
|
Market Cap
|
195
|
147,662
|
100,042
|
85,023
|
76,632
|
|
Net Debt
|
-97
|
8,094
|
-3,369
|
6,361
|
2,468
|
|
Enterprise Value (EV)
|
97
|
80,819
|
96,673
|
91,385
|
79,100
|
|
Revenue
|
76
|
35,957
|
13,418
|
9,702
|
17,265
|
| Balance Sheet |
|
|
|
|
|
| Total Assets |
122
|
100,407
|
21,787
|
21,239
|
54,298
|
| Total Liabilities |
42
|
43,069
|
6,116
|
11,930
|
35,238
|
| Shareholders Equity |
79
|
57,338
|
15,671
|
9,309
|
19,060.0
|
Where are the EBIT and EBITDA figures?
Certain companies and those in specific industries (for example insurance) do not report financial results at the EBIT
or EBITDA line. For these companies where Valuecruncher does not have EBIT or EBITDA numbers we exclude the valuation
metrics driven by these figures. Valuecruncher makes our other valuation metrics available for these companies.
To learn more about comparison analysis, please read our guide to comparison analysis
